David Y Chiang1, Nicolas Lebesgue2, David L Beavers1, Katherina M Alsina3, J Mirjam A Damen2, Niels Voigt4, Dobromir Dobrev4, Xander H T Wehrens5, Arjen Scholten6. 1. Cardiovascular Research Institute, Baylor College of Medicine, Houston, Texas; Department of Molecular Physiology & Biophysics, Baylor College of Medicine, Houston, Texas; Interdepartmental Program in Translational Biology and Molecular Medicine, Baylor College of Medicine, Houston, Texas. 2. Biomolecular Mass Spectrometry and Proteomics, Bijvoet Center for Biomolecular Research and Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, the Netherlands; Netherlands Proteomics Centre, the Netherlands. 3. Cardiovascular Research Institute, Baylor College of Medicine, Houston, Texas; Department of Molecular Physiology & Biophysics, Baylor College of Medicine, Houston, Texas. 4. Institute of Pharmacology, Faculty of Medicine, University Duisburg-Essen, Essen, Germany. 5. Cardiovascular Research Institute, Baylor College of Medicine, Houston, Texas; Department of Molecular Physiology & Biophysics, Baylor College of Medicine, Houston, Texas; Department of Medicine (Cardiology), Baylor College of Medicine, Houston, Texas. Electronic address: wehrens@bcm.edu. 6. Biomolecular Mass Spectrometry and Proteomics, Bijvoet Center for Biomolecular Research and Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, the Netherlands; Netherlands Proteomics Centre, the Netherlands; Janssen Infectious Diseases and Vaccines, Crucell Holland B.V., Leiden, the Netherlands. Electronic address: a.scholten@uu.nl.
Abstract
BACKGROUND: Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia, yet current pharmacological treatments are limited. Serine/threonine protein phosphatase type-1 (PP1), a major phosphatase in the heart, consists of a catalytic subunit (PP1c) and a large set of regulatory (R)-subunits that confer localization and substrate specificity to the holoenzyme. Previous studies suggest that PP1 is dysregulated in AF, but the mechanisms are unknown. OBJECTIVES: The purpose of this study was to test the hypothesis that PP1 is dysregulated in paroxysmal atrial fibrillation (PAF) at the level of its R-subunits. METHODS: Cardiac lysates were coimmunoprecipitated with anti-PP1c antibody followed by mass spectrometry-based, quantitative profiling of associated R-subunits. Subsequently, label-free quantification (LFQ) was used to evaluate altered R-subunit-PP1c interactions in PAF patients. R-subunits with altered binding to PP1c in PAF were further studied using bioinformatics, Western blotting (WB), immunocytochemistry, and coimmunoprecipitation. RESULTS: A total of 135 and 78 putative PP1c interactors were captured from mouse and human cardiac lysates, respectively, including many previously unreported interactors with conserved PP1c docking motifs. Increases in binding were found between PP1c and PPP1R7, cold-shock domain protein A (CSDA), and phosphodiesterase type-5A (PDE5A) in PAF patients, with CSDA and PDE5A being novel interactors validated by bioinformatics, immunocytochemistry, and coimmunoprecipitation. WB confirmed that these increases in binding cannot be ascribed to their changes in global protein expression alone. CONCLUSIONS: Subcellular heterogeneity in PP1 activity and downstream protein phosphorylation in AF may be attributed to alterations in PP1c-R-subunit interactions, which impair PP1 targeting to proteins involved in electrical and Ca(2+) remodeling. This represents a novel concept in AF pathogenesis and may provide more specific drug targets for treating AF.
BACKGROUND:Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia, yet current pharmacological treatments are limited. Serine/threonine protein phosphatase type-1 (PP1), a major phosphatase in the heart, consists of a catalytic subunit (PP1c) and a large set of regulatory (R)-subunits that confer localization and substrate specificity to the holoenzyme. Previous studies suggest that PP1 is dysregulated in AF, but the mechanisms are unknown. OBJECTIVES: The purpose of this study was to test the hypothesis that PP1 is dysregulated in paroxysmal atrial fibrillation (PAF) at the level of its R-subunits. METHODS: Cardiac lysates were coimmunoprecipitated with anti-PP1c antibody followed by mass spectrometry-based, quantitative profiling of associated R-subunits. Subsequently, label-free quantification (LFQ) was used to evaluate altered R-subunit-PP1c interactions in PAF patients. R-subunits with altered binding to PP1c in PAF were further studied using bioinformatics, Western blotting (WB), immunocytochemistry, and coimmunoprecipitation. RESULTS: A total of 135 and 78 putative PP1c interactors were captured from mouse and human cardiac lysates, respectively, including many previously unreported interactors with conserved PP1c docking motifs. Increases in binding were found between PP1c and PPP1R7, cold-shock domain protein A (CSDA), and phosphodiesterase type-5A (PDE5A) in PAF patients, with CSDA and PDE5A being novel interactors validated by bioinformatics, immunocytochemistry, and coimmunoprecipitation. WB confirmed that these increases in binding cannot be ascribed to their changes in global protein expression alone. CONCLUSIONS: Subcellular heterogeneity in PP1 activity and downstream protein phosphorylation in AF may be attributed to alterations in PP1c-R-subunit interactions, which impair PP1 targeting to proteins involved in electrical and Ca(2+) remodeling. This represents a novel concept in AF pathogenesis and may provide more specific drug targets for treating AF.
Authors: Thin-Thin Aye; Siddarth Soni; Toon A B van Veen; Marcel A G van der Heyden; Salvatore Cappadona; Andras Varro; Roel A de Weger; Nicolaas de Jonge; Marc A Vos; Albert J R Heck; Arjen Scholten Journal: J Mol Cell Cardiol Date: 2011-06-12 Impact factor: 5.000
Authors: Sonia Molina-Pinelo; Irene Ferrer; Carmen Blanco-Aparicio; Sandra Peregrino; Maria Dolores Pastor; Juan Alvarez-Vega; Rocio Suarez; Mar Verge; Juan J Marin; Javier Hernandez-Losa; Santiago Ramon y Cajal; Luis Paz-Ares; Amancio Carnero Journal: J Pathol Date: 2011-05-19 Impact factor: 7.996
Authors: Niels Voigt; Jordi Heijman; Qiongling Wang; David Y Chiang; Na Li; Matthias Karck; Xander H T Wehrens; Stanley Nattel; Dobromir Dobrev Journal: Circulation Date: 2013-11-18 Impact factor: 29.690
Authors: Juan Antonio Vizcaíno; Richard G Côté; Attila Csordas; José A Dianes; Antonio Fabregat; Joseph M Foster; Johannes Griss; Emanuele Alpi; Melih Birim; Javier Contell; Gavin O'Kelly; Andreas Schoenegger; David Ovelleiro; Yasset Pérez-Riverol; Florian Reisinger; Daniel Ríos; Rui Wang; Henning Hermjakob Journal: Nucleic Acids Res Date: 2012-11-29 Impact factor: 16.971
Authors: Katherina M Alsina; Mohit Hulsurkar; Sören Brandenburg; Daniel Kownatzki-Danger; Christof Lenz; Henning Urlaub; Issam Abu-Taha; Markus Kamler; David Y Chiang; Satadru K Lahiri; Julia O Reynolds; Ann P Quick; Larry Scott; Tarah A Word; Maria D Gelves; Albert J R Heck; Na Li; Dobromir Dobrev; Stephan E Lehnart; Xander H T Wehrens Journal: Circulation Date: 2019-06-12 Impact factor: 29.690
Authors: David Y Chiang; Katherina M Alsina; Eleonora Corradini; Martin Fitzpatrick; Li Ni; Satadru K Lahiri; Julia O Reynolds; Xiaolu Pan; Larry Scott; Albert J R Heck; Xander H T Wehrens Journal: Circulation Date: 2018-10-09 Impact factor: 29.690
Authors: Javier Barallobre-Barreiro; Shashi K Gupta; Anna Zoccarato; Rika Kitazume-Taneike; Marika Fava; Xiaoke Yin; Tessa Werner; Marc N Hirt; Anna Zampetaki; Alessandro Viviano; Mei Chong; Marshall Bern; Antonios Kourliouros; Nieves Domenech; Peter Willeit; Ajay M Shah; Marjan Jahangiri; Liliana Schaefer; Jens W Fischer; Renato V Iozzo; Rosa Viner; Thomas Thum; Joerg Heineke; Antoine Kichler; Kinya Otsu; Manuel Mayr Journal: Circulation Date: 2016-08-24 Impact factor: 29.690